In last trading session, Standard BioTools Inc (NASDAQ:LAB) saw 1.48 million shares changing hands with its beta currently measuring 1.55. Company’s recent per share price level of $1.07 trading at -$0.07 or -6.14% at ring of the bell on the day assigns it a market valuation of $406.41M. That closing price of LAB’s stock is at a discount of -156.07% from its 52-week high price of $2.74 and is indicating a premium of 11.21% from its 52-week low price of $0.95. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.15 million shares which gives us an average trading volume of 1.56 million if we extend that period to 3-months.
For Standard BioTools Inc (LAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Standard BioTools Inc (NASDAQ:LAB) trade information
Upright in the red during last session for losing -6.14%, in the last five days LAB remained trading in the green while hitting it’s week-highest on Tuesday, 05/13/25 when the stock touched $1.07 price level, adding 10.08% to its value on the day. Standard BioTools Inc’s shares saw a change of -38.86% in year-to-date performance and have moved 4.90% in past 5-day. Standard BioTools Inc (NASDAQ:LAB) showed a performance of -6.96% in past 30-days. Number of shares sold short was 18.44 million shares which calculate 16.27 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3.25 to the stock, which implies a rise of 67.08% to its current value. Analysts have been projecting 3.25 as a low price target for the stock while placing it at a high target of 3.25. It follows that stock’s current price would drop -203.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of -203.74% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.61% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 55.77% while estimates for its earnings growth in next 5 years are of 66.44%.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Insiders are in possession of 1.41% of company’s total shares while institution are holding 73.29 percent of that, with stock having share float percentage of 74.35%. Investors also watch the number of corporate investors in a company very closely, which is 73.29% institutions for Standard BioTools Inc that are currently holding shares of the company. CASDIN CAPITAL, LLC is the top institutional holder at LAB for having 63.96 million shares of worth $113.21 million. And as of 2024-06-30, it was holding 17.1782 of the company’s outstanding shares.
The second largest institutional holder is VIKING GLOBAL INVESTORS LP, which was holding about 58.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.7524 of outstanding shares, having a total worth of $103.81 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 9.17 shares of worth $9.81 million or 2.41% of the total outstanding shares. The later fund manager was in possession of 7.72 shares on Mar 31, 2025 , making its stake of worth around $8.26 million in the company or a holder of 2.03% of company’s stock.
